jnj-20210420
0000200406false00002004062021-04-202021-04-200000200406us-gaap:CommonStockMember2021-04-202021-04-200000200406jnj:A0.250NotesDue2022Member2021-04-202021-04-200000200406jnj:A0.650NotesDue2024Member2021-04-202021-04-200000200406jnj:A5.50NotesDue2024Member2021-04-202021-04-200000200406jnj:A1.150NotesDue2028Member2021-04-202021-04-200000200406jnj:A1.650NotesDue2035Member2021-04-202021-04-20


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): 
April 20, 2021
Johnson & Johnson
 (Exact name of registrant as specified in its charter)
  
New Jersey1-321522-1024240
(State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)

One Johnson & Johnson Plaza, New Brunswick, New Jersey  08933 
(Address of Principal Executive Offices)
 (Zip Code) 
Registrant's telephone number, including area code:
732-524-0400
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 
            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
               CFR 240.14d-2(b)) 
            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
               CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, Par Value $1.00JNJNew York Stock Exchange
0.250% Notes Due January 2022JNJ22New York Stock Exchange
0.650% Notes Due May 2024JNJ24CNew York Stock Exchange
5.50% Notes Due November 2024JNJ24BPNew York Stock Exchange
1.150% Notes Due November 2028JNJ28New York Stock Exchange
1.650% Notes Due May 2035JNJ35New York Stock Exchange
 
 




 
Item 2.02                      Results of Operations and Financial Condition
 
On April 20, 2021, Johnson & Johnson issued the attached press release announcing its sales and earnings for the first quarter ended April 4, 2021.
 
Item 9.01            Financial Statements and Exhibits

(d)     Exhibits. 
 
Exhibit No.
 
Description of Exhibit
 
104The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.




 
 
 


 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 Johnson & Johnson 
   (Registrant)
 
 
 
 
Date: April 20, 2021By:/s/ Robert J. Decker, Jr. 
  Robert J. Decker, Jr.
Controller
(Principal Accounting Officer)
 

Document

Exhibit 99.1

JOHNSON & JOHNSON REPORTS 2021 FIRST-QUARTER RESULTS:
2021 First Quarter Sales of $22.3 Billion reflecting strong growth of 7.9%, operational growth of 5.5%* and adjusted operational growth of 6.0%*
2021 First Quarter EPS of $2.32 increased 6.9%; adjusted EPS of $2.59 increased 12.6%*

Company increased 2021 Full-Year guidance for adjusted operational sales growth to 9.3%* and adjusted operational EPS growth to 16.8%* at the midpoint

New Brunswick, N.J. (April 20, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter. “Johnson & Johnson delivered a strong first quarter performance led by the above market growth of our Pharmaceutical business and continued recovery in Medical Devices,” said Alex Gorsky, Chairman and Chief Executive Officer. “The ability to deliver these results while simultaneously advancing our robust pipeline of life-enhancing medicines, products and solutions during these times is a testament to the strength and resilience of our business and the dedication of the 135,000 employees of Johnson & Johnson who strive every day to profoundly change the trajectory of health for humanity and make healthier communities for everyone, everywhere.”

OVERALL FINANCIAL RESULTS:
https://cdn.kscope.io/99ad27b1d076b4eb505013b8cddd8f97-a1q21overallfinancialresula.jpg

1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
4 Excludes intangible amortization expense and special items





REGIONAL SALES RESULTS:

https://cdn.kscope.io/99ad27b1d076b4eb505013b8cddd8f97-a1q21regionalfinancialresua.jpg

1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded


SEGMENT SALES RESULTS:

https://cdn.kscope.io/99ad27b1d076b4eb505013b8cddd8f97-a1q21salesbysegmentpng1a.jpg

1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded




First Quarter 2021 SEGMENT COMMENTARY:

Consumer Health
Consumer Health worldwide operational sales, excluding the net impact of acquisitions and divestitures, declined 2.9%* primarily driven by negative prior year comparisons related to the COVID-19 pantry loading in Q1 2020, mainly in over-the counter products. Partially offsetting the decline is growth in LISTERINE in oral care products, JOHNSON’S BABY in baby care products, international skin health/beauty products and NICORETTE in international over-the-counter products.


Pharmaceutical
Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 7.4%* driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. This growth was partially offset by biosimilar and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, and U.S. ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer.


Medical Devices
Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 8.8%*, and reflects the benefit of market recovery from COVID-19 impacts in the prior year. Contributors to growth were electrophysiology products in the Interventional Solutions business, worldwide biosurgery and energy products, and international endocutters in Advanced Surgery, wound closure products in General Surgery, contact lenses and surgery in the Vision business and trauma products in Orthopaedics; partially offset by knee products in Orthopaedics.



NOTABLE NEW ANNOUNCEMENTS IN THE QUARTER:
The information contained in this section should be read in conjunction with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases available online in the Investors section of the Company’s website at news releases.

Regulatory
Approvals
PONVORY (ponesimod) approved by U.S. FDA, an oral treatment for adults with relapsing multiple sclerosis proven superior to (teriflunomide) in reducing annual relapses and brain lesions(press release)
Johnson & Johnson Single-Shot COVID-19 Vaccine granted conditional marketing authorization by European Commission
(press release)
Johnson & Johnson Single-Shot COVID-19 Vaccine granted emergency use listing by the World Health Organization
(press release)
Johnson & Johnson COVID-19 Vaccine authorized by U.S. FDA for emergency use(press release)
SPRAVATO (Esketamine Nasal Spray) authorized in Europe for the rapid reduction of depressive symptoms in a psychiatric emergency for patients with major depressive disorder(press release)
MONOFOCAL INTRAOCULAR LENS - TECNIS EYHANCE AND TECNIS EYHANCE TORIC II IOLS - receives FDA approval for a next generation treatment for cataract patients(press release)
Regulatory
Submissions
Submission of supplemental new drug application to U.S. FDA by ViiV Healthcare for expanded use of CABENUVA (rilpivirine and cabotegravir) as an HIV treatment for use every two months(press release)
OtherJanssen provides update on Phase 3 ACIS Study in patients with metastatic castration-resistant prostate cancer treated with ERLEADA (apalutamide) and ZYTIGA (abiraterone acetate) combination ¹ (press release)
Johnson & Johnson announces advance purchase agreement with the African Vaccine Acquisition Trust for the Company’s COVID-19 vaccine candidate(press release)
PONVORY (ponesimod) receives positive CHMP opinion for the treatment of adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features(press release)
CAR-T Therapy Ciltacabtagene Autoleucel (Cilta-cel) accepted for accelerated assessment in Europe for the treatment of patients with heavily pretreated multiple myeloma(press release)
1 Subsequent to the quarter




FULL-YEAR 2021 GUIDANCE:

Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the Company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.

January 2021April 2021
($ in Billions, except EPS)    
Adjusted Operational Sales1,2
Change vs. Prior Year
8.0% - 9.5%8.7% - 9.9%
Operational Sales2
Change vs. Prior Year
$88.8B - $90.0B
7.5% – 9.0%
$89.3B - $90.3B
8.2% – 9.4%
Estimated Reported Sales3
Change vs. Prior Year
$90.5B - $91.7B
 9.5% – 11.0%
  $90.6B - $91.6B
 9.7% – 10.9%
Adjusted Operational EPS (Diluted)2,4
Change vs. Prior Year
 $9.25 - $9.45
   15.2% - 17.7%
$9.30 - $9.45
  15.8% - 17.7%
Adjusted EPS (Diluted)3,4
Change vs. Prior Year
  $9.40 - $9.60
    17.1% - 19.6%
$9.42 - $9.57
  17.3% - 19.2%
1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2 Non-GAAP financial measure; excludes the impact of translational currency
3 Calculated using Euro Average Rate: January 2021 = $1.21 and April 2021 = $1.19 (Illustrative purposes only)
4 Non-GAAP financial measure; excludes intangible amortization expense and special items

Other modeling considerations will be provided on the webcast.

WEBCAST INFORMATION:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investors section of the Company's website at events-and-presentations.

ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.





NON-GAAP FINANCIAL MEASURES:
*Operational sales growth excluding the impact of translational currency, adjusted operational sales growth excluding the net impact of acquisitions and divestitures and translational currency, as well as adjusted net earnings, adjusted diluted earnings per share and adjusted operational diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investors section of the Company's website at quarterly-results.

Copies of the financial schedules accompanying this earnings release are available on the Company’s website at quarterly-results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investors section of the Company's website at quarterly-results.

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021 including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in the Company’s most recently filed Quarterly Report on Form 10-Q and the Company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
Press Contacts:     Investor Contacts:

Christina Chan    Courtney Dugan     Christopher DelOrefice     Sarah Wood
(732) 524-6297    (347) 452-1061      (732) 524-2955     (732) 524-2617


Document

Exhibit 99.2


Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)FIRST QUARTER
Percent Change
20212020TotalOperationsCurrency
Sales to customers by
geographic area
U.S. $11,111  10,699  3.9 % 3.9  -
Europe 5,414  4,827 12.1  4.7  7.4
Western Hemisphere excluding U.S. 1,424  1,502  (5.1)0.0  (5.1)
Asia-Pacific, Africa 4,372  3,663  19.4  13.7  5.7
International 11,210  9,992  12.2  7.3  4.9
      
Worldwide $22,321  20,691  7.9 % 5.5  2.4
        
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.







Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)FIRST QUARTER
 Percent Change
20212020TotalOperationsCurrency
Sales to customers by
segment of business
Consumer Health
    U.S.$1,611 1,740 (7.4)%(7.4)— 
    International1,932 1,885 2.5 0.5 2.0 
3,543    3,625 (2.3)(3.3)1.0 
Pharmaceutical
    U.S.6,446 6,061 6.4 6.4— 
    International5,753 5,073 13.4 7.95.5 
12,199    11,134 9.6 7.12.5 
Medical Devices
    U.S.3,054    2,898 5.4 5.4 — 
    International3,525 3,034 16.2 10.5 5.7 
 6,579    5,932 10.9 8.0 2.9 
U.S.11,111 10,699 3.9 3.9 — 
International11,210 9,992 12.2 7.3 4.9 
Worldwide$22,321 20,691 7.9 %5.5 2.4 
   
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.






Johnson & Johnson and Subsidiaries 
Condensed Consolidated Statement of Earnings  
(Unaudited; in Millions Except Per Share Figures)FIRST QUARTER
20212020Percent
PercentPercentIncrease
Amountto SalesAmountto Sales(Decrease)
Sales to customers$22,321 100.0$20,691 100.07.9 
Cost of products sold7,063 31.77,062 34.10.0
Gross Profit15,258 68.313,629 65.912.0 
Selling, marketing and administrative expenses5,432 24.35,203 25.14.4 
Research and development expense3,178 14.22,580 12.523.2 
Interest (income) expense, net48 0.2 (42)(0.2)
Other (income) expense, net(882)(3.9)(679)(3.3)
Restructuring53 0.258 0.3
Earnings before provision for taxes on income7,429 33.36,509 31.514.1 
Provision for taxes on income1,232 5.5713 3.5 72.8 
Net earnings$6,197 27.8$5,796 28.06.9 
Net earnings per share (Diluted)$2.32 $2.17 6.9 
Average shares outstanding (Diluted)2,672.7 2,671.0 
Effective tax rate16.6 %11.0 %
Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income$8,291 37.1$7,244 35.014.5 
Net earnings$6,924 31.0$6,154 29.712.5 
Net earnings per share (Diluted)$2.59 $2.30 12.6 
Effective tax rate16.5 %15.0 %
(1) See Reconciliation of Non-GAAP Financial Measures.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.











Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
First Quarter
(Dollars in Millions Except Per Share Data)20212020
Net Earnings, after tax- as reported$6,197$5,796
Pre-tax Adjustments
Intangible Asset Amortization expense1,215 1,118
Litigation expense - 120
Restructuring related104 118
Acquisition, integration and divestiture related 1
(538)(962)
Unrealized (gains)/losses on securities 35 327
Medical Device Regulation 46  14
Tax Adjustments
Tax impact on special item adjustments 2
(113)(267)
Tax legislation and other tax related(22) (110)
Adjusted Net Earnings, after tax$6,924$6,154
Average shares outstanding (Diluted)2,672.7 2,671.0
Adjusted net earnings per share (Diluted)$2.59$2.30
Operational adjusted net earnings per share (Diluted)$2.49 
Notes:
1
Acquisition, integration and divestiture related for the first quarter of 2021 primarily includes the gain on the divestiture of two Pharmaceutical brands outside of the U.S. The first quarter of 2020 primarily includes a $983M Contingent Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition.
2
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.









Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Adjusted Operational Sales Growth (A)
 FIRST QUARTER 2021 ACTUAL vs. 2020 ACTUAL
 Segments
Consumer Health Pharmaceutical  Medical Devices  Total
 WW As Reported (2.3)%9.6 %10.9 %7.9 %
 U.S. (7.4)%6.4 %5.4 %3.9 %
 International 2.5 %13.4 %16.2 %12.2 %
 WW Currency 1.02.52.92.4
 U.S.
 International 2.05.55.74.9
 WW Operational (3.3)%7.1 %8.0 %5.5 %
 U.S. (7.4)%6.4 %5.4 %3.9 %
 International 0.5 %7.9 %10.5 %7.3 %
General Surgery
Advanced Sterilization Products0.60.2
 U.S. 0.00.0
 International 1.20.4
All Other Acquisitions and Divestitures0.40.30.10.3
 U.S. 0.5(0.2)0.20.0
 International 0.40.90.00.5
WW Adjusted Operational(2.9)%7.4 %8.8 %6.0 %
 U.S. (6.9)%6.2 %5.6 %3.9 %
 International 0.9 %8.8 %11.8 %8.2 %
Note: Percentages are based on actual, non-rounded figures and may not sum
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.
 











Johnson & Johnson
Segment Sales
(Dollars in Millions)
FIRST QUARTER
% Change
20212020Reported
Operational (1)
Currency
CONSUMER HEALTH SEGMENT (2)
OTC
US$599689(13.0)%(13.0)%— %
Intl575659(12.8)(16.6)3.8 
WW1,1751,348(12.9)(14.8)1.9 
SKIN HEALTH / BEAUTY
US634659(3.9)(3.9)— 
Intl52945815.7 12.3 3.4 
WW1,163 1,1174.1 2.8 1.3 
ORAL CARE
US163176(7.2)(7.2)— 
Intl25421916.0 13.9 2.1 
WW417 395 5.7 4.5 1.2 
BABY CARE
US96924.2 4.2 — 
Intl2932698.9 11.3 (2.4)
WW389 361 7.7 9.5 (1.8)
WOMEN'S HEALTH
US34(25.8)(25.8)— 
Intl219228(3.9)(2.2)(1.7)
WW222232(4.3)(2.6)(1.7)
WOUND CARE / OTHER
US115119(3.0)(3.0)— 
Intl615217.6 14.2 3.4 
WW1771713.3 2.2 1.1 
TOTAL CONSUMER HEALTH
US1,611 1,740 (7.4)(7.4) 
Intl1,932 1,885 2.5 0.5 2.0 
WW$3,543 3,625 (2.3)%(3.3)%1.0 %
See footnotes at end of schedule






Johnson & Johnson
Segment Sales
(Dollars in Millions)
FIRST QUARTER
% Change
20212020Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3)
IMMUNOLOGY
US$2,4132,4100.1 %0.1 %— %
Intl1,5011,22822.3 15.9 6.4 
WW3,9143,6387.6 5.5 2.1 
     REMICADE
     US489625(21.7)(21.7)— 
     US Exports (4)
57110(48.4)(48.4)— 
     Intl232256(9.4)(12.1)2.7 
     WW777990(21.5)(22.2)0.7 
     SIMPONI / SIMPONI ARIA
     US255272(5.9)(5.9)— 
     Intl30725818.9 13.8 5.1 
     WW5625296.2 3.7 2.5 
     STELARA
     US1,3311,2179.4 9.4 — 
     Intl81760335.6 27.6 8.0 
     WW2,1481,81918.1 15.4 2.7 
     TREMFYA
     US274 187 46.3 46.3 — 
     Intl143 109 32.0 23.1 8.9 
     WW418 296 41.0 37.8 3.2 
     OTHER IMMUNOLOGY
     US7  **— 
     Intl2 3 (38.4)(36.3)(2.1)
     WW8 3 ***
INFECTIOUS DISEASES
US51243617.4 17.4 — 
Intl4944832.3 (2.2)4.5 
WW1,0079209.5 7.1 2.4 
     COVID-19 VACCINE
     US100**— 
     Intl— — — 
     WW100**— 
     EDURANT / rilpivirine
     US10 12 (12.3)(12.3)— 
     Intl233 212 9.8 0.9 8.9 
     WW243 224 8.6 0.2 8.4 
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
     US380396(3.8)(3.8)— 
     Intl166184(9.9)(10.4)0.5 
     WW546579(5.8)(5.9)0.1 
     OTHER INFECTIOUS DISEASES
     US2129(27.0)(27.0)— 
     Intl96879.7 7.4 2.3 
     WW1171160.6 (1.2)1.8 
See footnotes at end of schedule





Johnson & Johnson
Segment Sales
(Dollars in Millions)
FIRST QUARTER
% Change
20212020Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
NEUROSCIENCE
US$7717483.2 %3.2 %— %
Intl9499104.3 0.4 3.9
WW1,7211,6583.8 1.6 2.2
     CONCERTA / methylphenidate
     US4752(9.6)(9.6)
     Intl1231184.5(0.4)4.9
     WW1711710.2(3.2)3.4
     INVEGA SUSTENNA / XEPLION / INVEGA
     TRINZA / TREVICTA
     US5895448.3 8.3 
     Intl376339 11.0 4.5 6.5
     WW9658839.4 6.9 2.5
     RISPERDAL CONSTA
     US6776(11.8)(11.8)
     Intl8994(4.8)(8.8)4.0
     WW157170(7.9)(10.1)2.2
     OTHER NEUROSCIENCE
     US6775(9.8)(9.8)
     Intl3613600.2 (0.9)1.1
     WW428435(1.5)(2.5)1.0
ONCOLOGY
US1,3771,17517.2 17.2 
Intl2,193 1,839 19.3 12.9 6.4
WW3,5703,01318.5 14.6 3.9
     DARZALEX
     US691 463 49.2 49.2 
     Intl674 474 42.2 35.3 6.9
     WW1,365 937 45.6 42.2 3.4
     ERLEADA
     US171 119 44.0 44.0 — 
     Intl90 24 ** *
     WW261 143 82.8 79.7 3.1 
     IMBRUVICA
     US444 432 2.8 2.8 
     Intl680 599 13.5 7.6 5.9
     WW1,125 1,031 9.0 5.6 3.4
     ZYTIGA / abiraterone acetate
     US50139 (64.2)(64.2)
     Intl5885526.6 0.06.6
     WW638690(7.6)(12.9)5.3
     OTHER ONCOLOGY (5)
     US21 22 (5.1)(5.1)
     Intl161190(15.3)(19.3)4.0
     WW182212(14.2)(17.9)3.7
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
FIRST QUARTER
% Change
20212020Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
PULMONARY HYPERTENSION
US$573 486 18.0 %18.0 %— %
Intl288 260 10.8 5.6 5.2 
WW861 745 15.5 13.7 1.8 
     OPSUMIT
     US272 229 18.5 18.5 — 
     Intl179 160 11.5 6.3 5.2 
     WW450 389 15.6 13.5 2.1 
     UPTRAVI
     US259 212 21.9 21.9 — 
     Intl46 38 23.0 15.7 7.3 
     WW305 250 22.0 20.9 1.1 
     OTHER PULMONARY HYPERTENSION
     US42 44 (3.5)(3.5)— 
     Intl63 62 1.4 (2.1)3.5 
     WW105 106 (0.6)(2.7)2.1 
See footnotes at end of schedule





Johnson & Johnson
Segment Sales
(Dollars in Millions)
FIRST QUARTER
% Change
20212020Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3) Continued)
CARDIOVASCULAR / METABOLISM / OTHER
US$799806(0.9)%(0.9)%— %
Intl328354(7.2)(11.3)4.1 
WW1,1271,160(2.8)(4.1)1.3 
     XARELTO
     US589 527 11.7 11.7 — 
     Intl  — — — 
     WW589 527 11.7 11.7 — 
     INVOKANA / INVOKAMET
     US87 117 (26.1)(26.1)— 
     Intl63 58 9.2 4.2 5.0 
     WW150 175 (14.4)(16.1)1.7 
     PROCRIT / EPREX
     US62 76 (18.3)(18.3)— 
     Intl64 79 (18.1)(22.2)4.1 
     WW127 155 (18.2)(20.3)2.1 
     OTHER
     US60 85 (28.8)(28.8)— 
     Intl201 217 (7.7)(11.5)3.8 
     WW261 302 (13.6)(16.4)2.8 
TOTAL PHARMACEUTICAL
US6,4466,0616.4 6.4  
Intl5,7535,07313.4 7.9 5.5 
WW$12,19911,1349.6 %7.1 %2.5 %
See footnotes at end of schedule





Johnson & Johnson
Segment Sales
(Dollars in Millions)
FIRST QUARTER
% Change
20212020Reported
Operational (1)
Currency
MEDICAL DEVICES SEGMENT (2)
INTERVENTIONAL SOLUTIONS
US$434 365 19.0 %19.0 %— %
Intl514 36242.0 34.0 8.0 
WW949 72730.4 26.4 4.0 
ORTHOPAEDICS
US1,249 1,250 (0.1)(0.1)— 
Intl864 788 9.7 3.1 6.6 
WW2,113 2,038 3.7 1.2 2.5 
     HIPS
     US210 206 2.4 2.4 — 
     Intl146 132 11.2 4.5 6.7 
     WW357 337 5.8 3.2 2.6 
     KNEES
     US185 214 (13.5)(13.5)— 
     Intl132 130 2.0 (4.1)6.1 
     WW317 343 (7.6)(9.9)2.3 
     TRAUMA
     US450 407 10.7 10.7 — 
     Intl282 247 14.4 7.7 6.7 
     WW733 654 12.1 9.5 2.6 
     SPINE, SPORTS & OTHER
     US403 423 (4.8)(4.8)— 
     Intl303 280 8.4 1.7 6.7 
     WW706 703 0.4 (2.2)2.6 
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
FIRST QUARTER
% Change
20212020Reported
Operational (1)
Currency
MEDICAL DEVICES SEGMENT (2) (Continued)
SURGERY
US$898 844 6.5 %6.5 %— %
Intl1,474 1,257 17.3 11.7 5.6 
WW2,372 2,100 12.9 9.6 3.3 
     ADVANCED
US405 381 6.5 6.5  
Intl713 567 25.7 19.5 6.2 
WW1,118 948 18.0 14.3 3.7 
     GENERAL
US493 463 6.5 6.5  
Intl761 690 10.3 5.3 5.0 
WW1,254 1,153 8.8 5.8 3.0 
VISION
US472 439 7.4 7.4  
Intl673 628 7.3 3.9 3.4 
WW1,145 1,067 7.3 5.4 1.9 
     CONTACT LENSES / OTHER
US371 346 7.2 7.2  
Intl486 467 4.0 0.9 3.1 
WW857 814 5.3 3.5 1.8 
     SURGICAL
US101 93 8.2 8.2 — 
Intl187 160 17.0 12.9 4.1 
WW288 253 13.7 11.2 2.5 
TOTAL MEDICAL DEVICES
US3,054 2,898 5.4 5.4  
Intl3,525 3,034 16.2 10.5 5.7 
WW$6,579 5,932 10.9 %8.0 %2.9 %
Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-
rounded figures and, therefore, may not recalculate precisely.
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures
(4) Reported as U.S. sales
(5) Refer to supplemental schedule








Johnson & Johnson
Supplemental Sales Information
(Dollars in Millions)
Prior quarter amounts have been reclassified to
conform to current quarter products disclosure
201920202020
Full YearQ1Q2Q3Q4Full Year
PHARMACEUTICAL SEGMENT (1)
     OTHER ONCOLOGY (2)
US70 2220212083
Intl1,087 190185181183738
WW1,158 212204203202821
Note: Columns and rows within tables may not add due to rounding.
(1) Unaudited
(2) Other Oncology is inclusive of VELCADE, which was previously disclosed separately